Table of Contents
Executive Summary — 5
SWOT
Analysis — 6
Zimbabwe Pharmaceuticals And Healthcare
Industry SWOT — 6
Zimbabwe Political
SWOT — 7
Zimbabwe Economic SWOT — 8
Zimbabwe Business Environment SWOT — 9
Pharmaceutical
Business Environment Ratings — 10
Table: Middle East and
Africa Pharmaceutical Business Environment Ratings — 10
Limits of Potential Returns — 11
Risks to Realisation of
Returns — 11
Zimbabwe – Market
Summary — 13
Regulatory Regime — 14
Intellectual Property Developments — 14
Pricing and
Reimbursement Issues — 15
Public Drug
Procurement — 15
Industry
Developments — 17
Epidemiology — 17
Communicable Diseases — 18
Cholera
Crisis — 18
HIV/AIDS Situation — 20
Healthcare System — 22
Healthcare
Funding — 24
Recent Healthcare System
Developments — 25
Health
Insurance — 25
Healthcare Staff — 26
Pharmaceutical Sector — 28
Recent Pharmaceutical Sector
Developments — 30
Table: ARV Prices Available Through
Direct Purchase From Roche (CHF) — 34
Pharmacy
Sector — 34
Traditional Medicine — 35
Biotechnology Sector Developments — 35
Medical
Devices — 36
Industry Forecast
Scenario — 37
Overall Market
Forecasts — 37
Table: Zimbabwe - Drug Market Forecast,
Historical Data and Forecasts — 38
Key Growth Factors
– Industry — 39
Key Growth Factors –
Macroeconomic — 41
Table: Zimbabwe - Economic Activity,
2006-2013 — 42
Prescription Drug Market
Forecast — 43
Table: Zimbabwe - Prescription Drug Market
Indicators, Historical Data and Forecasts (US$mn unless otherwise
indicated) — 44
Patented Drug Market
Forecast — 45
Table: Zimbabwe - Patented Market Forecast,
Historical Data and Forecasts — 45
Generic Drug Market
Forecast — 46
Table: Zimbabwe - Generic Drug Market
Indicators*, Historical Data and Forecasts — 47
OTC Drug
Market Forecast — 48
Table: Zimbabwe - OTC Drug Market
Forecast, Historical Data and Forecasts (US$mn unless otherwise
indicated) — 49
Pharmaceutical Trade
Forecasts — 50
Table: Zimbabwe - Pharmaceutical Trade
Balance, Historical Data and Forecasts (US$mn) — 51
Other
Healthcare Data Forecasts — 52
Table: Zimbabwe - Other
Healthcare Forecasts, Historical Data and Forecasts — 52
Key Risks to BMI Forecasts — 53
Competitive
Landscape — 54
Company Profiles — 55
Multinational Companies — 55
Ranbaxy — 55
Pfizer — 57
Novartis — 59
Sanofi-Aventis — 60
Merck & Co — 61
GlaxoSmithKline — 62
Indigenous Companies — 64
Datlabs — 64
Varichem Laboratories — 66
CAPS
Holdings — 68
Country Snapshot: Zimbabwe Demographic
Data — 71
Section 1: Population — 71
Table: Demographic Indicators, 2005-2030 — 71
Table:
Rural/Urban Breakdown, 2005-2030 — 72
Section 2: Education
and Healthcare — 72
Table: Education,
2000-2003 — 72
Table: Vital Statistics,
2005-2030 — 72
Section 3: Labour Market and Spending
Power — 73
Table: Employment Indicators, 1997 And
1999* — 73
Table: Average Annual Manufacturing Wages,
1996-2002 — 73
BMI Forecast
Modelling — 74
How We Generate Our Pharmaceutical Industry
Forecasts — 74
Pharmaceutical Business Environment Ratings
Methodology — 75
Ratings Overview — 75
Table: Pharmaceutical Business Environment Indicators — 76
Weighting — 77
Table: Weighting Of
Components — 77
Sources — 77
| 
View Cart
